Journal article
Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone.
Abstract
PURPOSE: A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer. The purpose of this study was to assess the effects of these treatments on health-related quality of life (HQL).
PATIENTS AND METHODS: Men with metastatic prostate cancer (n = 161) were randomized to receive either daily prednisone alone or mitoxantrone (every 3 weeks) plus …
Authors
Osoba D; Tannock IF; Ernst DS; Neville AJ
Journal
Journal of Clinical Oncology, Vol. 17, No. 6, pp. 1654–1663
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
June 1999
DOI
10.1200/jco.1999.17.6.1654
ISSN
0732-183X
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdenocarcinomaAgedAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsCross-Over StudiesDisease ProgressionHumansLymphatic MetastasisMaleMiddle AgedMitoxantronePalliative CarePrednisoneProstatic NeoplasmsQuality of LifeSurveys and QuestionnairesTime FactorsTreatment Outcome